Amarantus Bioscience Holdings, Inc.
OperatingBiotech · San Francisco, CA
Financials
FY2008–FY2018 (no data for FY2016, FY2017) · from SEC filings · hover any figure for its sourceChart shows the most recent 8 fiscal years; 1 earlier year is in the table below.
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Cap table
Share counts as of Jan 9, 2020| Class | Outstanding | Votes / share | Converts | As converted | Votes | Liquidation | Last price |
|---|---|---|---|---|---|---|---|
| Series B Preferred stockpreferred | 249,999 | — | 0.33 × common stock | 0.03% | 0.1% | — | — |
| Series Epreferred | 1,140 | none | — | 0% | 0% | 1× | — |
| Series Hpreferred | 455 | — | — | 0% | 0% | — | — |
| Series Apreferred | 250 | none | — | 0% | 0% | — | — |
| Common Stock | 252,504,841 | 1 | — | 100.0% | 99.9% | — | — |
| Total | 252,756,685 | 252,589,185.67 as converted | 100% | 100% |
Shares outstanding over timein today's share terms
Changes in named holdersshares in today's terms · % of all shares at the time
- Gerald E. Commissiong53K (1.81%) Apr 2013 → 57K (1.18%) Apr 2014 → 59K (0.83%) Apr 2015 → 444K (0.77%) May 2016 → 250K (99.3%) Sep 2019
- Robert L. Harris27K (0.93%) Apr 2013 → 70K (1.43%) Apr 2014 → 78K (1.1%) Apr 2015 → 196K (0.34%) May 2016 → 25K (9.92%) Sep 2019
- Marc Faerber7K (0.25%) Apr 2013 → 9K (0.18%) Apr 2014 → 15K (0.22%) Apr 2015 → 178K (0.31%) May 2016
- Dr. John W. Commissiong132K (4.49%) Apr 2013 → 136K (2.8%) Apr 2014 → 136K (1.93%) Apr 2015 → 383K (0.66%) May 2016
Principal holders% as the filing states it, Jan 9, 2020
- Gerald E. Commissiong249,999 Series B99.0%of votes
- Robert L. Harris24,986 Common0.01%of votes
- Gerald E. Commissiong400,931 Common0%of votes
- Everyone else (not named in filings)0.99%
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. “As converted” counts each class in the shares it converts into. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
6 peopleNames and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.
SEC filings
View all 51 filings on EDGAR- Form 1-A-WJan 10, 20200001213900-20-000719EDGAR
- Form 1-A/AJan 9, 20200001213900-20-000667EDGAR
- Form 1-AJan 9, 20200001213900-20-000662EDGAR
- Form 1-ASep 27, 20190001213900-19-019161EDGAR
- Form DMar 12, 20180001213900-18-002828EDGAR
- Form 10-QJun 1, 20160001213900-16-013942EDGAR
- Form 10-KMay 16, 20160001213900-16-013437EDGAR
- Form 10-QNov 23, 20150001213900-15-009040EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.